【摘要】 目的 探讨灯盏花素注射液联合血管紧张素转换酶抑制剂（ACEI）依那普利治疗糖尿病早期肾病的临床效果。 方法 2006年10月-2009年12月，将59例临床确诊2型糖尿病早期肾病的患者随机分为治疗组（n=30）与对照组（n=29）。对照组在基本治疗的基础上应用依那普利，治疗组在基本治疗的基础上联合应用依那普利和灯盏花素注射液，疗程均为3周。观察治疗前后两组患者24 h尿微量白蛋白排泄率（UAER）、全血黏度、血浆黏度、甘油三酯（TG）、尿素氮（BUN）、血肌酐（SCr）的变化。 结果 两组患者治疗前后自身对比，24 h UAER均有明显下降（Plt;0.05）；治疗组UAER下降较对照组更为明显（Plt;0.05）。 结论 ACEI联合灯盏花素，其降低24 h UAER疗效优于单纯ACEI疗效，还可有效降低全血黏度和血浆黏度，降低纤维蛋白原含量，改善患者血液流变性。【Abstract】 Objective To investigate the therapeutic effects of breviscapine combined with angiotensin converting enzyme inhibitor (enalapril) on early diabetic nephropathy. Methods A total of 59 patients with early diabetic nephropathy diagnosed between October 2006 and December 2009 were randomly divided into treatment group (n=30) and control group (n=29). The patients in treatment group were treated by breviscapine combined with enalapril, while the patients were treated with only enalapril in the control group. All of the patients were treated for three weeks. Urinaryalbuminexcretion (UAE), whole blood viscosity, plasma viscosity, triglycercide, blood urea nitrogen and serum creatinine in the two groups were detected before and after the treatment. Results After the threatment, UAE decreased in both of the two groups compared with the value before the treatment (Plt;0.05); the decrease in treatment groups was more obvious than that in the control group (Plt;0.05). Conclusion The combination of breviscapine and enalapril is effective on early diabetic nephropathy.
Objective To report the progression of breviscapine’s protective effect to hepatic ischemia-reperfusion injury. Methods Pertinent literatures and journal articles published in recent years were reviewed, and the progression of breviscapine protecting hepatic ischemia-reperfusion injury in the experimental and clinical research were analyzed and summarized. Results The role of breviscapine is considerable extensive. It can protect hepatic ischemia-reperfusion injury by anti-oxyradical and anti-lipid peroxidation, inhibiting mitochondrial damage, intracellular calcium overload, intra-thromboxane and apoptosis, improving microcirculation, and so on. Conclusion Breviscapine plays a protective role in hepatic ischemia-reperfusion injury, and it will be of great value to application and research.
ObjectiveTo study on the compatible stability of brevescapine injection in common solvents. MethodsBrevescapine injection was added into 0.9% sodium chloride injection,5% glucose injection,10% glucose injection (100,250,and 500 mL) respectively at room temperature.The pH value and visual appearance of the admixture were observed at immediate 0,1,2,4,6 hours after Brevescapine injection was added into the solvents.Scutellarin concentration was determined by the method of high performance liquid chromatography (HPLC). ResultsNo significant change was found in appearance and pH value of the admixture.And Scutellarin concentration changed obviously in the admixture of 100 mL 0.9% sodium chloride injection,100 mL 10% glucose injection and the three types of 5% glucose injection. ConclusionBrevescapine injections have better compatibility with 250 mL and 500 mL 0.9% sodium chloride injection,and it is incompatible with 5% glucose injection.In addition,the admixture injection should be finished within six hours.